Cue Biopharma Inc Ordinary Shares CUE
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if CUE is a good fit for your portfolio.
News
-
Cue Biopharma Reports Fourth Quarter and Full Year 2023 Financial Results and Updated Business Highlights
-
Cue Biopharma to Host Business Update Call and Webcast
-
Cue Biopharma’s Lead Clinical Asset, CUE-101, to be Featured at the 2024 Multi-disciplinary Head and Neck Cancers Symposium
-
Cue Biopharma to Present Corporate Update at the Oppenheimer 34th Annual Healthcare Life Sciences Conference
Trading Information
- Previous Close Price
- $1.58
- Day Range
- $1.50–1.59
- 52-Week Range
- $1.48–5.04
- Bid/Ask
- $0.00 / $0.00
- Market Cap
- $73.45 Mil
- Volume/Avg
- 161,467 / 263,042
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 12.54
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Cue Biopharma Inc is a clinical-stage biopharmaceutical company. It is developing a novel and proprietary class of biologics drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its objective is to provide patients suffering from cancer and autoimmune disease with dramatically improved therapeutic outcomes through the platform of biologic drug product candidates. The other products under pipeline are CUE-101 as a Monotherapy, CUE-101 + Pembrolizumab, CUE-102, CUE-103 and others.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 53
- Website
- https://www.cuebiopharma.com
Comparables
Valuation
|
Metric
|
CUE
|
CLDX
|
TYRA
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 1.92 | 5.02 | 3.15 |
Price/Sales | 12.54 | 271.21 | — |
Price/Cash Flow | — | — | — |
Price/Earnings
CUE
CLDX
TYRA
Financial Strength
|
Metric
|
CUE
|
CLDX
|
TYRA
|
|---|---|---|---|
Quick Ratio | 2.94 | 13.69 | 13.27 |
Current Ratio | 3.01 | 13.87 | 13.80 |
Interest Coverage | −41.89 | — | — |
Quick Ratio
CUE
CLDX
TYRA
Profitability
|
Metric
|
CUE
|
CLDX
|
TYRA
|
|---|---|---|---|
Return on Assets (Normalized) | −56.12% | −30.49% | −22.50% |
Return on Equity (Normalized) | −85.75% | −33.19% | −23.73% |
Return on Invested Capital (Normalized) | −65.47% | −32.85% | −27.79% |
Return on Assets
CUE
CLDX
TYRA
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Qxfshtdglb | Jdt | $557.8 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Wvtgtkhm | Vbfyzc | $104.6 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Nrnyzct | Zywlpyh | $98.8 Bil | |
MRNA
| Moderna Inc | Cpykzpwqx | Lrj | $38.8 Bil | |
ARGX
| argenx SE ADR | Nvdzhgrgs | Spm | $21.3 Bil | |
BNTX
| BioNTech SE ADR | Lxmzdryk | Xhcy | $20.8 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Jwpsycxc | Vhdzsb | $18.4 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Xntwpvdbm | Tkfgjl | $17.5 Bil | |
RPRX
| Royalty Pharma PLC Class A | Trfqrzmbt | Gztcftx | $12.4 Bil | |
INCY
| Incyte Corp | Jpgslwqvd | Jdqrs | $11.9 Bil |